A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...

MS relapses are more common in spring and summer, coinciding with warmer, drier weather and atmospheric changes, a study ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...

Heat sensitivity in multiple sclerosis is well known, but doctors say cold weather can also worsen symptoms. From nerve ...

Elsa Mendoza navigates life with multiple sclerosis, using a wheelchair while her son, Fernando, excels as a quarterback ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

The CEMIP enzyme inhibits the growth of oligodendrocytes and may serve as a therapeutic target to boost myelin repair in MS, ...

New research shows some gut bacteria mimic myelin, tricking immunity to attack nerves and worsen MS. Non-inflammatory ...

WEDNESDAY, Dec. 17, 2025 (HealthDay News) — An over-the-counter supplement called lipoic acid might help slow the loss of ...

Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...